AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
NEW YORK, Dec. 21, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acorda Therapeutics, Inc. (NASDAQ:ACOR) who purchased shares between April 18, 2016 and November 14, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) the drug treatment tozadenant entailed significant undisclosed safety risks; (ii) accordingly, the Company had overstated tozadenant’s approval prospects and commercial viability; (iii) the Company had likewise overstated the benefits of the Biotie Acquisition; and (iv) as a result of the foregoing, Acorda’s shares traded at artificially inflated prices during the Class Period. On November 15, 2017, Acorda revealed it had ceased enrolling new patients in its Phase 3 trial of its Parkinson’s treatment due to patient deaths.
Shareholders have until January 17, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/acorda-therapeutics-inc?wire=1.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
